Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMSWUGE)

• Drug Name: Telbivudine Drug Info
• Synonyms: Epavudine; LLT; LdT; Sebivo; Telbivudin; Tyzeka; Telbivudine [USAN]; LDT600; NB 02B; NV 02B; L-Deoxythymidine; L-Thymidine; L-dT; LDT-600; NV-02B; Tyzeka (TN); Beta-L-Thymidine; Telbivudine (USAN/INN); Tyzake/Sebivo (TN); Tyzeka, Sebivo, Telbivudine; 1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-(2-Deoxy-beta-L-erythropentafuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; 2'-Deoxy-L-thymidine
• Therapeutic Class: Antiviral Agents
• Cross-matching ID:
  PubChem CID: 159269
  ChEBI ID: CHEMBL374731
  CAS Number: CAS 3424-98-4
  TTD Drug ID: D0CL9S
  ACDINA Drug ID: D00655

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
DNA replication	2.05	9.28e-3	34/36 (94.44%)	PCNA;FEN1;MCM2;...
Mineral absorption	1.88	3.25e-2	48/60 (80%)	MT1E;MT1H;MT1F;...
Cell cycle	1.80	4.95e-2	110/124 (88.71%)	PCNA;CCNB1;CDC45;...
Retinol metabolism	-1.71	3.58e-2	41/68 (60.29%)	ADH1B;DHRS3;ADH5;...
Antigen processing and presentation	-1.71	3.79e-2	60/78 (76.92%)	CTSS;PDIA3;CANX;...
Autoimmune thyroid disease	-1.73	3.64e-2	46/53 (86.79%)	TG;CD86;HLA-DPB1;...
Riboflavin metabolism	-1.75	3.24e-2	7/8 (87.5%)	ACP1;ACP5;ENPP1;...
Peroxisome	-1.77	2.64e-2	72/82 (87.8%)	AGXT;EHHADH;IDH1;...
Primary bile acid biosynthesis	-1.81	2.57e-2	15/17 (88.24%)	CYP46A1;SLC27A5;AKR1C4;...
Mitophagy	-1.84	2.32e-2	56/68 (82.35%)	CALCOCO2;CSNK2B;JUN;...
Type I diabetes mellitus	-1.86	1.98e-2	38/43 (88.37%)	HLA-DPB1;CD80;IL1A;...
Allograft rejection	-1.88	1.95e-2	32/38 (84.21%)	CD86;HLA-DPB1;CD80;...
Metabolism of xenobiotics by cytochrome P450	-1.89	2.43e-2	49/77 (63.64%)	CYP3A5;CYP2D6;ALDH3B1;...
Selenocompound metabolism	-1.92	2.16e-2	11/17 (64.71%)	SEPHS2;SCLY;PAPSS2;...
Ribosome	-2.07	5.41e-3	113/158 (71.52%)	RPL4;RPS19;RPL15;...
Graft-versus-host disease	-2.10	1.08e-2	32/42 (76.19%)	CD86;HLA-DPB1;CD80;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.04uM - 10uM	24H	Hide ▲

Fibrocystic breast disease

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A (Parent)	CVCL_0598	Homo sapiens	1.11uM - 10uM	3H, 6H, 12H, 24H	Hide ▲

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	3H, 24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H	Show ▼